New York, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report 'Ofev (nintedanib) - Drug Insight and Market Fo ...

Among patients participating in the pivotal SENSCIS trial that compared nintedanib with placebo for SSc-ILD, more than four times as many patients assigned to the active drug developed signs of ...

Nintedanib, a medication approved for the treatment of idiopathic pulmonary fibrosis, slows the decline in lung function among patients with a broad range of scarring lung diseases.

Ofev (nintedanib) and cost. ... The drug’s cost with and without insurance can depend on several factors, such as whether Ofev has a savings program you’re eligible for.

Since November 2014 nintedanib (trade name: ... (IQWiG) examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.

Nintedanib in lung cancer: Added benefit depends on disease severity ... However, in patients with brain metastases, the new drug has more disadvantages than chemotherapy with docetaxel alone.

The FDA has granted Orphan Drug designation to nintedanib (Boehringer Ingelheim) for the treatment of systemic sclerosis (SSc, or scleroderma), including the associated interstitial lung disease ...

Nintedanib slows the deterioration of lung functionality in patients with limited cutaneous SSc and interstitial lung disease, according to data derived from Allanore Y, et al. Rheumatology. 2023 ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for nintedanib for children and adolescents 6 to 17 years of age with fibrosing interstitial lung ...

image: Nintedanib could be used in the treatment of drug-resistant gastrointestinal stromal tumors. view more Credit: LIU Juan. A research team led by Prof. LIU Qingsong and LIU Jing from the ...

Sofosbuvir, mirabegron and nintedanib — all approved within the past 9 years — are ... The identification of drugs involved in this adverse drug reaction (ADR) ...